Lipidology, An Issue of Endocrinology and Metabolism Clinics of North America

 
 
Elsevier (Verlag)
  • 1. Auflage
  • |
  • erschienen am 27. Februar 2016
  • |
  • 100 Seiten
 
E-Book | ePUB mit Adobe DRM | Systemvoraussetzungen
E-Book | PDF mit Adobe DRM | Systemvoraussetzungen
978-0-323-44505-4 (ISBN)
 

This issue of Endocrinology and Metabolism Clinics examines the timely topic of Lipidology. In addition to the New Recommendations - ACC/AHA Lipid Guidelines, the issue also includes Familial Hypercholesterolemia; LDL Apheresis; Lipids in Pregnancy and Women; Diabetes and Lipidology; Diabetic Dyslipidemia; Fatty Liver Disease; Lipids and HIV Disease; Residual Risk; and Statins' effects on diabetes, cognition, and liver safety.

  • Englisch
  • St Louis
  • |
  • USA
Elsevier Health Sciences
  • 3,72 MB
978-0-323-44505-4 (9780323445054)
0323445055 (0323445055)
weitere Ausgaben werden ermittelt
  • Front Cover
  • Lipidology
  • Copyright
  • Contributors
  • EDITORS
  • AUTHORS
  • Contents
  • Familial Hypercholesterolemia
  • New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk: A Comparison of the 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines with the 2014 National Lipid Association Recommendations for Patient-Centered Management of Dyslipidemia
  • Lipoprotein Apheresis
  • Dyslipidemia in Pregnancy
  • Women's Health Considerations for Lipid Management
  • Statins and Diabetes
  • Statins and Cognitive Side Effects: What Cardiologists Need to Know
  • Statins and the Liver
  • Genetic Testing in Hyperlipidemia
  • Lipid Management in Human Immunodeficiency Virus
  • Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
  • Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
  • Dyslipidemia in Special Ethnic Populations
  • ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA
  • FORTHCOMING ISSUES
  • June 2016
  • September 2016
  • December 2016
  • RECENT ISSUES
  • December 2015
  • September 2015
  • June 2015
  • Erratum
  • Familial Hypercholesterolemia
  • Key points
  • INTRODUCTION
  • Pathophysiology
  • Genetics of Familial Hypercholesterolemia
  • Prevalence of Familial Hypercholesterolemia
  • PATIENT EVALUATION
  • Screening Strategies
  • Diagnosis
  • Genetic Testing
  • Prognosis
  • Risk assessment tools
  • TREATMENT
  • Lifestyle and Noncholesterol Risk Factor Modification
  • Pharmacologic Therapy
  • Combination Therapy
  • Low-Density Lipoprotein Apheresis
  • Homozygous Familial Hypercholesterolemia: Treatment Considerations
  • SURGICAL THERAPY
  • TREATMENT RESISTANCE/COMPLICATIONS
  • Side Effects of Medications
  • Statins and muscle problems
  • Statins and liver issues
  • DRUGS IN DEVELOPMENT
  • SUMMARY
  • REFERENCES
  • New Cholesterol Guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk
  • Key points
  • THE 2013 AMERICAN COLLEGE OF CARDIOLOGY/AMERICAN HEART ASSOCIATION GUIDELINE ON THE TREATMENT OF BLOOD CHOLESTEROL
  • Scope and Methodology
  • Groups Benefiting from Statin Therapy ("Statin Benefit Groups")
  • Pooled Cohort Risk Equations for Atherosclerotic Cardiovascular Disease Risk Assessment
  • Low-Density Lipoprotein Cholesterol Treatment Targets
  • THE 2014 NATIONAL LIPID ASSOCIATION RECOMMENDATIONS FOR PATIENT-CENTERED MANAGEMENT OF DYSLIPIDEMIA
  • Scope and Methodology
  • Atherogenic Cholesterol (Non-High-Density Lipoprotein Cholesterol and Low-Density Lipoprotein Cholesterol)
  • Assessment of Atherosclerotic Cardiovascular Disease Risk
  • Treatment Algorithm
  • COMPARISON AND CONTRASTS OF THE NEW GUIDELINES
  • Low-Density Lipoprotein Cholesterol Treatment Goals
  • Combination Statin Therapy
  • Implications of the IMProved Reduction of Outcomes: Vytorin Efficacy International Trial
  • Atherosclerotic Cardiovascular Disease Risk Assessment
  • Importance of Shared Decision Making and a Patient-Centered Approach
  • Lipid Targets and Low-Density Lipoprotein Cholesterol Monitoring
  • The Way Forward
  • REFERENCES
  • Lipoprotein Apheresis
  • Key points
  • INTRODUCTION
  • CRITERIA FOR LIPOPROTEIN APHERESIS
  • POTENTIAL PATIENT POPULATION WHO QUALIFY FOR LIPOPROTEIN APHERESIS
  • BILLING AND CODING INFORMATION
  • APPROVED LIPOPROTEIN APHERESIS MACHINES IN THE UNITED STATES
  • Futura, B Braun, Melsungen, Germany
  • Heparin-induced extracorporeal low-density lipoprotein precipitation
  • MAO3 Liposorber, Kaneka, Osaka, Japan
  • Dextran sulfate low-density lipoprotein adsorption
  • Further lipoprotein apheresis information
  • Contraindications/Complications/Adverse Events
  • Special Points of Interest
  • Clinical Benefit
  • LIPOPROTEINS AND OTHER PROTEINS ALTERED BY LIPOPROTEIN APHERESIS
  • Low-density Lipoprotein (Apolipoprotein B-containing Particles)
  • High-density Lipoprotein Cholesterol
  • Triglycerides and Other Apolipoproteins
  • Lp(a)
  • Inflammatory and Other Markers Affected
  • RHEOLOGY
  • ALTERNATIVE USES
  • SUMMARY
  • ACKNOWLEDGMENTS
  • REFERENCES
  • Dyslipidemia in Pregnancy
  • Key points
  • INTRODUCTION
  • CHOLESTEROL AND FETAL DEVELOPMENT
  • PREVALENCE OF CARDIOVASCULAR DISEASE RISK FACTORS
  • FETAL CONSIDERATIONS
  • MATERNAL CONSIDERATIONS
  • POSTPARTUM CONSIDERATIONS
  • REFERENCES
  • Women's Health Considerations for Lipid Management
  • Key points
  • INTRODUCTION
  • DETECTION, MANAGEMENT, AND TREATMENT OF DYSLIPIDEMIA IN PREGNANCY
  • Lipid Values in Normal and Abnormal Pregnancies
  • Optimum Strategies for Detection and Treatment of Dyslipidemia in Pregnancy
  • Differential Diagnosis and Evaluation of Hypertriglyceridemia in Pregnancy
  • Treatment and Monitoring of Dyslipidemia Associated with Pregnancy
  • Familial Hyperlipidemia Monitoring and Treatment
  • Recommendations for Women with Dyslipidemia Who Are Breastfeeding
  • LONG-TERM IMPLICATIONS OF COMPLICATIONS IN PREGNANCY
  • Polycystic Ovary Syndrome
  • SCREENING FOR ASSOCIATED DYSLIPIDEMIA IN POLYCYSTIC OVARIAN SYNDROME
  • TREATMENT OF DYSLIPIDEMIA IN POLYCYSTIC OVARIAN SYNDROME
  • DYSLIPIDEMIA TREATMENT AND UNIQUE CHALLENGES FOR WOMEN WITH POLYCYSTIC OVARIAN SYNDROME
  • Contraception
  • LIPID CHANGES WITH DIFFERENT FORMS OF CONTRACEPTION
  • Combined Oral Contraceptives
  • NON-COMBINED ORAL CONTRACEPTIVE METHODS
  • Intrauterine Devices
  • Progestin Only
  • Permanent Sterilization
  • MENOPAUSE TRANSITION
  • Lipid Changes During Menopause
  • CURRENT RECOMMENDATIONS FOR HORMONE THERAPY
  • REFERENCES
  • Statins and Diabetes
  • Key points
  • INTRODUCTION
  • CLINICAL TRIAL EVIDENCE REGARDING STATIN USE AND DIABETES
  • West of Scotland Coronary Prevention Study
  • Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin
  • Metaanalyses of Statin Clinical Trials and the Risk:Benefit Ratio
  • Observational Studies of the Relationship Between Statin Use and Diabetes Risk
  • Mechanisms for Causality Between Use of Statins and Increased Diabetes Risk
  • Impact of Statin Therapy on Glycemic Control in Patients with Diabetes Mellitus
  • Clinical Guidance
  • Criteria for Screening
  • Potential Use of Nonstatin Add-On Therapy as an Alternative to Statin Intensification in Primary Prevention
  • SUMMARY
  • REFERENCES
  • Statins and Cognitive Side Effects
  • Key points
  • INTRODUCTION
  • COGNITIVE IMPAIRMENT DEFINED AND IMPLICATIONS FOR IATROGENESIS
  • OBJECTIVE
  • POSSIBLE MECHANISMS
  • LIMITS AND STRENGTHS OF CURRENT DATA AND CONSIDERATIONS FOR VASCULAR RISK FACTOR CONTROL
  • SUGGESTIONS FOR CLINICIANS
  • SUMMARY
  • REFERENCES
  • Statins and the Liver
  • Key points
  • INTRODUCTION
  • Patient Evaluation Overview
  • Pharmacologic Treatment Options and Complications
  • Evaluation of Outcome and Recommendations in Specific Liver Diseases
  • Hepatitis C
  • Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
  • Primary Biliary Cirrhosis and Cholestatic Liver Disease
  • Liver Transplantation
  • SUMMARY/DISCUSSION
  • REFERENCES
  • Genetic Testing in Hyperlipidemia
  • Key points
  • INTRODUCTION
  • GENETIC TESTING IN FAMILIAL HYPERCHOLESTEROLEMIA
  • Current Clinical Criteria for Diagnosis of Familial Hypercholesterolemia
  • Genetic Testing to Improve Diagnostic Accuracy
  • Genetic Testing in Screening for Familial Hypercholesterolemia
  • Genetic Testing in the Treatment of Familial Hypercholesterolemia
  • OTHER POTENTIAL USES OF GENETIC TESTING
  • GENETIC TESTING IN HYPERTRIGLYCERIDEMIA
  • DISADVANTAGES OF GENETIC TESTING
  • CURRENT TESTS AVAILABLE
  • SUMMARY
  • ACKNOWLEDGMENTS
  • REFERENCES
  • Lipid Management in Human Immunodeficiency Virus
  • Key points
  • INTRODUCTION
  • BACKGROUND
  • Human Immunodeficiency Virus
  • Human Immunodeficiency Virus and Risk for Cardiovascular Disease
  • Antiretroviral Therapy
  • Lipid Changes with Human Immunodeficiency Virus Infection and Antiretroviral Therapy
  • GUIDELINES FOR THE MANAGEMENT OF DYSLIPIDEMIA IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS
  • Risk Stratification and Scores
  • Lipid Targets for Patients Living With Human Immunodeficiency Virus
  • Low-density lipoprotein cholesterol
  • Triglycerides
  • High-density lipoprotein cholesterol
  • MANAGEMENT OF DYSLIPIDEMIA IN PATIENTS INFECTED WITH HUMAN IMMUNODEFICIENCY VIRUS
  • When to Use Measures of Residual Risk
  • History and Physical Examination
  • Laboratory Evaluation
  • Therapeutic Lifestyle Modification
  • Medications
  • Statins
  • Efficacy
  • Drug-drug interactions between antiretroviral therapy and statins
  • Statin use with antiretroviral therapy pharmacokinetic enhancers
  • Treatment of patients coinfected with hepatitis C
  • Other classes of antiretroviral therapy
  • Side effects of statin drugs
  • Liver side effects
  • Muscle
  • Neurologic
  • Diabetes and insulin resistance
  • Nonstatin drugs for the treatment of dyslipidemia
  • Intestine absorption inhibitors
  • Niacin (Nicotinic acid)
  • Bile acid sequestrants
  • Treatment of Hypertriglyceridemia
  • Fibrates
  • Fish oil
  • Niacin
  • Other Issues Related to Drug Therapy
  • Cost of drugs and coverage
  • Combination with other nonstatin drugs
  • Familial Hypercholesterolemia
  • Switching Antiretroviral Therapy
  • Monitoring and Follow-up
  • SUMMARY
  • REFERENCES
  • Managing Residual Risk After Myocardial Infarction Among Individuals with Low Cholesterol Levels
  • Key points
  • INTRODUCTION
  • EPIDEMIOLOGY AND SIGNIFICANCE
  • CURRENT GUIDELINES FOR POST-MYOCARDIAL INFARCTION MANAGEMENT AND SUPPORTING EVIDENCE
  • Cardiac Rehabilitation and Lifestyle Changes
  • Evidence-Based Post-Myocardial Infarction Pharmacologic Treatment
  • Antiplatelet therapy
  • Renin-angiotensin system inhibition
  • ß-Blocker therapy
  • Statin therapy
  • Complications and Comorbidities
  • MANAGING SERUM LIPIDS IN THE CONTEMPORARY ERA
  • Other Lipid Targets
  • SUMMARY
  • REFERENCES
  • Management of Hypertriglyceridemia for Prevention of Atherosclerotic Cardiovascular Disease
  • Key points
  • EPIDEMIOLOGY AND PATHOPHYSIOLOGY OF HYPERTRIGLYCERIDEMIA
  • HYPERTRIGLYCERIDEMIA VERSUS ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: ASSOCIATION AND POTENTIAL CAUSATION
  • Mechanisms of Accelerated Atherogenesis in Hypertriglyceridemia
  • The Atherogenic Dyslipidemia
  • Genetic Evidence for a Causal Role of Hypertriglyceridemia in Atherosclerotic Cardiovascular Disease
  • EFFECTS OF TRIGLYCERIDE LEVEL-LOWERING MEDICATIONS ON ATHEROSCLEROTIC CARDIOVASCULAR DISEASE EVENTS: RANDOMIZED CLINICAL TRIALS
  • Randomized Clinical Trials of Fenofibrate
  • Randomized Clinical Trials of Omega-3
  • Randomized Clinical Trials of Niacin
  • Summary of Completed Randomized Clinical Trials of Triglyceride Level Lowering Versus Atherosclerotic Cardiovascular Disease
  • Ongoing Randomized Clinical Trials of Triglyceride Level Lowering Versus Atherosclerotic Cardiovascular Disease
  • TREATMENT RECOMMENDATIONS FOR HYPERTRIGLYCERIDEMIA
  • Current Guidelines for Management of Hypertriglyceridemia
  • Diet and Lifestyle Treatment of Hypertriglyceridemia
  • Treatment of Secondary Factors in Hypertriglyceridemia
  • Pharmacotherapy Treatment Recommendations Adjunctive to Current Guidelines
  • REFERENCES
  • Dyslipidemia in Special Ethnic Populations
  • Key points
  • INTRODUCTION
  • PREVALENCE OF DYSLIPIDEMIA SUBTYPES AMONG SPECIAL RACIAL/ETHNIC GROUPS
  • Low-Density Lipoprotein Cholesterol
  • High-Density Lipoprotein Cholesterol
  • Triglycerides
  • DYSLIPIDEMIA-RELATED MORTALITY IN SPECIAL RACIAL/ETHNIC GROUPS
  • TREATMENT OF DYSLIPIDEMIA
  • Overview
  • Racial/Ethnic Differences in Risk Stratification
  • Race/Ethnic Differences in Statin Response
  • Statin metabolism and drug sensitivity
  • Statin efficacy in Asian populations
  • Lifestyle Modification in Special Racial/Ethnic Groups
  • SUMMARY
  • REFERENCES
  • Index

Dateiformat: EPUB
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat EPUB ist sehr gut für Romane und Sachbücher geeignet - also für "fließenden" Text ohne komplexes Layout. Bei E-Readern oder Smartphones passt sich der Zeilen- und Seitenumbruch automatisch den kleinen Displays an. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Dateiformat: PDF
Kopierschutz: Adobe-DRM (Digital Rights Management)

Systemvoraussetzungen:

Computer (Windows; MacOS X; Linux): Installieren Sie bereits vor dem Download die kostenlose Software Adobe Digital Editions (siehe E-Book Hilfe).

Tablet/Smartphone (Android; iOS): Installieren Sie bereits vor dem Download die kostenlose App Adobe Digital Editions (siehe E-Book Hilfe).

E-Book-Reader: Bookeen, Kobo, Pocketbook, Sony, Tolino u.v.a.m. (nicht Kindle)

Das Dateiformat PDF zeigt auf jeder Hardware eine Buchseite stets identisch an. Daher ist eine PDF auch für ein komplexes Layout geeignet, wie es bei Lehr- und Fachbüchern verwendet wird (Bilder, Tabellen, Spalten, Fußnoten). Bei kleinen Displays von E-Readern oder Smartphones sind PDF leider eher nervig, weil zu viel Scrollen notwendig ist. Mit Adobe-DRM wird hier ein "harter" Kopierschutz verwendet. Wenn die notwendigen Voraussetzungen nicht vorliegen, können Sie das E-Book leider nicht öffnen. Daher müssen Sie bereits vor dem Download Ihre Lese-Hardware vorbereiten.

Weitere Informationen finden Sie in unserer E-Book Hilfe.


Download (sofort verfügbar)

73,77 €
inkl. 19% MwSt.
Download / Einzel-Lizenz
ePUB mit Adobe DRM
siehe Systemvoraussetzungen
PDF mit Adobe DRM
siehe Systemvoraussetzungen
Hinweis: Die Auswahl des von Ihnen gewünschten Dateiformats und des Kopierschutzes erfolgt erst im System des E-Book Anbieters
E-Book bestellen

Unsere Web-Seiten verwenden Cookies. Mit der Nutzung dieser Web-Seiten erklären Sie sich damit einverstanden. Mehr Informationen finden Sie in unserem Datenschutzhinweis. Ok